Clarma Capital

www.clarmacapital.com

VCMatch tracks Clarma Capital as an investor focused on Biotech, Medtech, and Pharma companies, Seed and Series A rounds, and Europe, United Kingdom, and Switzerland markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A

Focus Areas

Biotech, Medtech, Pharma

Geography

Europe, United Kingdom, and Switzerland

Investment Thesis

CLARMA CAPITAL targets early-stage European life sciences startups with regulated products (medical devices, medicinal products, diagnostics) that are grounded in solid science and have potential to change the standard of care. The firm combines sector-specialist deal selection with hands-on value creation — working “in collaboration with management teams” to drive growth, secure follow-on funding, build strategic partnerships, improve operational efficiency, support regulatory approval pathways, and pursue clearly defined exit routes (preferably by acquisitions or mergers). CLARMA leverages decades of senior-level operational experience and an extensive sector network to accelerate portfolio companies toward commercialisation and impact.

Is Clarma Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Clarma Capital is most relevant for founders raising Seed and Series A rounds in Biotech, Medtech, and Pharma, especially across Europe, United Kingdom, and Switzerland.

Focus statement

CLARMA CAPITAL "focuses on investing in European life sciences startups, particularly those at the forefront of medical device, medicinal product, and diagnostic innovation." The firm primarily invests at seed and early stages in regulated products with significant addressable markets and commercially-minded management teams.

Value Add

Sector-specialist focus on regulated life sciences (medical devices, medicinal products, diagnostics) rather than general tech or consumer VC.
Geographic focus on Europe with team locations in London, Switzerland, Dublin and Central Europe.
Hands-on, operational value-add: support across follow-on funding, strategic partnerships, operational efficiency, business development and regulatory guidance (incl. FDA support).
Experienced senior team and advisors with decades of private equity, asset management and life sciences operational backgrounds.
AIFM registration: explicit commitment to a "stringent regulatory framework" promoting transparency and stability.
Clear exit orientation: preference for exits "preferably by acquisitions or mergers."
Explicit ESG commitment: ensures portfolio companies implement systems and processes reflective of ESG priorities.